Eli Lilly CDR (CAD Hedged)

A new analysis from the EMPA-KIDNEY trial demonstrates that empagliflozin is cost-effective for chronic kidney disease treatment, improving quality-adjusted life years while reducing healthcare costs.

BeyondSpring's Plinabulin combined with radiation and PD-1 inhibitors achieved a 23% overall response rate and 54% disease control rate in patients who failed prior checkpoint inhibitor therapy.

The Scottish Medicines Consortium has recommended Theramex's Eladynos (abaloparatide) for treating osteoporosis in postmenopausal women at very high risk of fracture through NHS Scotland.

Biocon Ltd. is seeking regulatory approval for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting Canada as its first major market entry by 2026.

Protagonist Therapeutics has selected PN-477, a novel triple agonist peptide targeting GLP-1, GIP, and GCG receptors, as a development candidate for obesity treatment with both oral and injectable formulations.

AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.

Laverock Therapeutics has expanded its seed funding round to more than £20 million, with the latest £6.5 million extension led by Calculus Capital and including participation from Eli Lilly and Company.

Karnataka's Health and Family Welfare Department has formally requested the Drug Controller General of India to investigate alleged ethical violations in clinical trials at HealthCare Global Enterprises Ltd (HCG) in Bengaluru.

Total M&A deal value in Alzheimer's disease jumped from $2 billion in 2022 to $18 billion in 2024, representing a 780% increase following the approval of disease-modifying treatments.

Longeveron Inc. has appointed Than Powell as Chief Business Officer effective July 7, 2025, to oversee partnering efforts for Alzheimer's disease and international strategy for hypoplastic left heart syndrome programs.